SARS-CoV-2 Spike Protein Vaccine-Induced Immune Imprinting Reduces Nucleocapsid Protein Antibody Response in SARS-CoV-2 Infection. 2022

Juan F Delgado, and Mónica Vidal-Pla, and M Carmen Moya, and Mateu Espasa, and Antonio Casabella, and Manel Seda, and Joan Calvet, and Jordi Gratacós, and Rosa M Serrano, and Pilar Peña
Immunology Unit, Laboratory Service, Parc Taulí Hospital Universitari, Institut d'Investigació i Innovació Parc Taulí (I3PT), Universitat Autònoma de Barcelona, Departament de Medicina, Sabadell, Spain.

Immune imprinting or original antigenic sin (OAS) is the process by which the humoral memory response to an antigen can inhibit the response to new epitopes of that antigen originating from a second encounter with the pathogen. Given the situation of the COVID-19 pandemic, multiple vaccines have been developed against SARS-CoV-2 infection. These vaccines are directed to the spike protein (S protein) of the original variant of Wuhan D614G. Vaccine memory immune response against S protein in noninfected subjects could inhibit, through the OAS mechanism, the response to new epitopes of SARS-CoV-2 after infection. The present study analyzes whether the memory antibody B cell response generated by mRNA vaccines against S protein can inhibit the primary antibody immune response to other SARS-CoV-2 antigens, such as nucleocapsid protein (N protein). SARS-CoV-2 primary infection in vaccinated healthcare workers (HCWs) produced significantly lower titers of anti-N antibodies than that in nonvaccinated HCWs: 5.7 (IQR 2.3-15.2) versus 12.2 (IQR 4.2-32.0), respectively (p = 0.005). Therefore, spike protein vaccine-induced immune imprinting (original antigenic sin) reduces N protein antibody response.

UI MeSH Term Description Entries
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000086382 COVID-19 A viral disorder generally characterized by high FEVER; COUGH; DYSPNEA; CHILLS; PERSISTENT TREMOR; MUSCLE PAIN; HEADACHE; SORE THROAT; a new loss of taste and/or smell (see AGEUSIA and ANOSMIA) and other symptoms of a VIRAL PNEUMONIA. In severe cases, a myriad of coagulopathy associated symptoms often correlating with COVID-19 severity is seen (e.g., BLOOD COAGULATION; THROMBOSIS; ACUTE RESPIRATORY DISTRESS SYNDROME; SEIZURES; HEART ATTACK; STROKE; multiple CEREBRAL INFARCTIONS; KIDNEY FAILURE; catastrophic ANTIPHOSPHOLIPID ANTIBODY SYNDROME and/or DISSEMINATED INTRAVASCULAR COAGULATION). In younger patients, rare inflammatory syndromes are sometimes associated with COVID-19 (e.g., atypical KAWASAKI SYNDROME; TOXIC SHOCK SYNDROME; pediatric multisystem inflammatory disease; and CYTOKINE STORM SYNDROME). A coronavirus, SARS-CoV-2, in the genus BETACORONAVIRUS is the causative agent. 2019 Novel Coronavirus Disease,2019 Novel Coronavirus Infection,2019-nCoV Disease,2019-nCoV Infection,COVID-19 Pandemic,COVID-19 Pandemics,COVID-19 Virus Disease,COVID-19 Virus Infection,Coronavirus Disease 2019,Coronavirus Disease-19,SARS Coronavirus 2 Infection,SARS-CoV-2 Infection,Severe Acute Respiratory Syndrome Coronavirus 2 Infection,COVID19,2019 nCoV Disease,2019 nCoV Infection,2019-nCoV Diseases,2019-nCoV Infections,COVID 19,COVID 19 Pandemic,COVID 19 Virus Disease,COVID 19 Virus Infection,COVID-19 Virus Diseases,COVID-19 Virus Infections,Coronavirus Disease 19,Disease 2019, Coronavirus,Disease, 2019-nCoV,Disease, COVID-19 Virus,Infection, 2019-nCoV,Infection, COVID-19 Virus,Infection, SARS-CoV-2,Pandemic, COVID-19,SARS CoV 2 Infection,SARS-CoV-2 Infections,Virus Disease, COVID-19,Virus Infection, COVID-19
D000086402 SARS-CoV-2 A species of BETACORONAVIRUS causing atypical respiratory disease (COVID-19) in humans. The organism was first identified in 2019 in Wuhan, China. The natural host is the Chinese intermediate horseshoe bat, RHINOLOPHUS affinis. 2019 Novel Coronavirus,COVID-19 Virus,COVID19 Virus,Coronavirus Disease 2019 Virus,SARS Coronavirus 2,SARS-CoV-2 Virus,Severe Acute Respiratory Syndrome Coronavirus 2,Wuhan Coronavirus,Wuhan Seafood Market Pneumonia Virus,2019-nCoV,2019 Novel Coronaviruses,COVID 19 Virus,COVID-19 Viruses,COVID19 Viruses,Coronavirus 2, SARS,Coronavirus, 2019 Novel,Coronavirus, Wuhan,Novel Coronavirus, 2019,SARS CoV 2 Virus,SARS-CoV-2 Viruses,Virus, COVID-19,Virus, COVID19,Virus, SARS-CoV-2,Viruses, COVID19
D000917 Antibody Formation The production of ANTIBODIES by proliferating and differentiated B-LYMPHOCYTES under stimulation by ANTIGENS. Antibody Production,Antibody Response,Antibody Responses,Formation, Antibody,Production, Antibody,Response, Antibody,Responses, Antibody
D000939 Epitopes Sites on an antigen that interact with specific antibodies. Antigenic Determinant,Antigenic Determinants,Antigenic Specificity,Epitope,Determinant, Antigenic,Determinants, Antigenic,Specificity, Antigenic
D014612 Vaccines Suspensions of killed or attenuated microorganisms (bacteria, viruses, fungi, protozoa), antigenic proteins, synthetic constructs, or other bio-molecular derivatives, administered for the prevention, amelioration, or treatment of infectious and other diseases. Vaccine
D058873 Pandemics Epidemics of infectious disease that have spread to many countries, often more than one continent, and usually affecting a large number of people. Pandemic
D019590 Nucleocapsid Proteins Viral proteins found in either the NUCLEOCAPSID or the viral core (VIRAL CORE PROTEINS). Viral N Proteins,Viral Nucleoproteins,Nucleocapsid Protein,Viral N Protein,N Protein, Viral,N Proteins, Viral,Nucleoproteins, Viral,Proteins, Viral N
D064370 Spike Glycoprotein, Coronavirus A class I viral fusion protein that forms the characteristic spikes, or peplomers, found on the viral surface that mediate virus attachment, fusion, and entry into the host cell. During virus maturation, it is cleaved into two subunits: S1, which binds to receptors in the host cell, and S2, which mediates membrane fusion. Spike Glycoprotein, Bovine Coronavirus,Spike Glycoproteins, Coronavirus,E2 Spike Glycoprotein, Coronavirus,Glycoprotein S, Coronavirus,Spike Glycoprotein S1, Coronavirus,Spike Protein S2, Coronavirus,Spike Protein, Coronavirus,Coronavirus Spike Glycoprotein,Coronavirus Spike Protein

Related Publications

Juan F Delgado, and Mónica Vidal-Pla, and M Carmen Moya, and Mateu Espasa, and Antonio Casabella, and Manel Seda, and Joan Calvet, and Jordi Gratacós, and Rosa M Serrano, and Pilar Peña
October 2021, Infection,
Juan F Delgado, and Mónica Vidal-Pla, and M Carmen Moya, and Mateu Espasa, and Antonio Casabella, and Manel Seda, and Joan Calvet, and Jordi Gratacós, and Rosa M Serrano, and Pilar Peña
February 2004, Biochemical and biophysical research communications,
Juan F Delgado, and Mónica Vidal-Pla, and M Carmen Moya, and Mateu Espasa, and Antonio Casabella, and Manel Seda, and Joan Calvet, and Jordi Gratacós, and Rosa M Serrano, and Pilar Peña
April 2021, bioRxiv : the preprint server for biology,
Juan F Delgado, and Mónica Vidal-Pla, and M Carmen Moya, and Mateu Espasa, and Antonio Casabella, and Manel Seda, and Joan Calvet, and Jordi Gratacós, and Rosa M Serrano, and Pilar Peña
November 2021, Trends in immunology,
Juan F Delgado, and Mónica Vidal-Pla, and M Carmen Moya, and Mateu Espasa, and Antonio Casabella, and Manel Seda, and Joan Calvet, and Jordi Gratacós, and Rosa M Serrano, and Pilar Peña
March 2022, Clinical laboratory,
Juan F Delgado, and Mónica Vidal-Pla, and M Carmen Moya, and Mateu Espasa, and Antonio Casabella, and Manel Seda, and Joan Calvet, and Jordi Gratacós, and Rosa M Serrano, and Pilar Peña
July 2021, The Lancet. Microbe,
Juan F Delgado, and Mónica Vidal-Pla, and M Carmen Moya, and Mateu Espasa, and Antonio Casabella, and Manel Seda, and Joan Calvet, and Jordi Gratacós, and Rosa M Serrano, and Pilar Peña
December 2023, Vaccines,
Juan F Delgado, and Mónica Vidal-Pla, and M Carmen Moya, and Mateu Espasa, and Antonio Casabella, and Manel Seda, and Joan Calvet, and Jordi Gratacós, and Rosa M Serrano, and Pilar Peña
March 2022, Vaccines,
Juan F Delgado, and Mónica Vidal-Pla, and M Carmen Moya, and Mateu Espasa, and Antonio Casabella, and Manel Seda, and Joan Calvet, and Jordi Gratacós, and Rosa M Serrano, and Pilar Peña
August 2022, EJIFCC,
Juan F Delgado, and Mónica Vidal-Pla, and M Carmen Moya, and Mateu Espasa, and Antonio Casabella, and Manel Seda, and Joan Calvet, and Jordi Gratacós, and Rosa M Serrano, and Pilar Peña
February 2022, Multiple sclerosis and related disorders,
Copied contents to your clipboard!